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Case RepoRt
A 49-year-old white man with blood group AB, D+ was found to 
have alloanti-Jka and -K when he developed a delayed hemolytic 
transfusion reaction before allogeneic hematopoietic stem cell 
transplant (HSCT). Given that his stem cell donor was blood group 
O, D+, Jk(a+), K–, rituximab was added to his conditioning regimen 
of fludarabine and melphalan to prevent hemolysis of engrafting 
Jk(a+) donor red blood cells. The patient proceeded to receive a 
peripheral blood stem cell transplant from a matched unrelated 
donor with no adverse events. To our knowledge, this is the first 
case of successful management of major non-ABO incompatibility 
caused by anti-Jka in a patient receiving an allogeneic HSCT 
reported in the literature. Immunohematology 2013;29: 
11–14.
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ABO mismatch is well characterized in the setting of 
hematopoietic stem cell transplant (HSCT). Because of the 
disparate genetic locations of HLA and ABO genes, ABO 
mismatch occurs in 30 to 50 percent of transplants.1 Red 
blood cell (RBC)–incompatible transplantation does not 
seem to have an adverse effect on transplant outcomes, such 
as engraftment, graft-versus-host disease (GVHD), relapse, 
or survival.2 However, it does carry the risk of hemolytic 
transfusion reactions (HTR), and it must be managed 
appropriately with interventions such as graft processing and 
proper blood component support.
RBC incompatibility can be classified into two categories. 
Major incompatibility is when the recipient has antibodies 
directed against donor RBC antigens. Minor incompatibility 
is defined as a donor having antibodies directed against 
recipient RBC antigens. Bidirectional incompatibility, usually 
in a group A donor with a group B recipient or vice versa, is 
when there is both major and minor incompatibility. Major 
incompatibility carries the risk of acute HTR and also delayed 
RBC recovery after transplant. Minor incompatibility can 
result in “passenger lymphocyte syndrome,” in which the 
donor B lymphocytes produce antibodies against recipient 
RBCs that cause a delayed hemolytic transfusion reaction 7 to 
12 days after transplantation.
Patients undergoing HSCT require frequent RBC 
transfusions owing to both the underlying disease and 
treatment with chemotherapy or radiation.3 Frequent 
transfusions predispose patients to developing alloantibodies 
to non-ABO RBC antigens. RBC alloantibodies may become 
undetectable over time and with restimulation can cause 
a delayed HTR if their past existence is not known before 
transfusion.4 Non-ABO antigens such as those in the Rh, Kell, 
and Kidd blood group systems have been implicated as targets 
for passenger lymphocyte syndrome after transplant.5–8
We present a patient who developed an unusual form 
of bidirectional incompatibility in the form of minor ABO 
incompatibility, being a group AB recipient with a group O 
donor, and major non-ABO incompatibility, with preformed 
anti-Jka directed against the donor’s Jk(a+) RBCs.
Case Report
A 49-year-old man was diagnosed with primary 
myelofibrosis in 2007. He was treated with hydroxyurea 
until May 2011, when he developed worsening anemia and 
thrombocytopenia that did not improve after hydroxyurea was 
discontinued. Bone marrow biopsy revealed advanced reticulin 
fibrosis. The patient had massive splenomegaly of 26 cm. His 
blood group was AB, D+, and he had a negative screening test 
for RBC alloantibodies. He had received 38 units of group AB, 
D+ RBC transfusions over a period of 8 months. Because his 
antibody screening test was negative, neither the patient nor 
any of the 38 RBC units were phenotyped for antigens beyond 
the standard A, B, and D. At this point it was decided that the 
patient needed an allogeneic HSCT.
The patient was admitted to our hospital for a matched 
unrelated donor HSCT. He received reduced-intensity 
conditioning with fludarabine 25 mg/m2/day given 
intravenously from Day –9 to Day –5 and melphalan 140 mg/
m2 given intravenously on Day –4. GVHD prophylaxis was 
initiated with tacrolimus 0.02 mg/kg/day continuous infusion 
starting on Day –3 and sirolimus 12 mg on Day –3 and 4 mg 
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daily thereafter. Peripheral blood stem cells were mobilized 
from the donor with granulocyte colony-stimulating factor, 
and 8 × 106 CD34+ cells/kg were infused into patient. Patient 
and donor were 10 of 10 HLA matched, with minor ABO 
incompatibility as the donor was group O, D+.
On admission to our hospital, the patient’s screening 
test for unexpected RBC antibodies was positive, but no 
specific antibody could be identified. Because of the positive 
antibody screen and because the prospective stem cell donor 
was group O, RBC units selected for transfusion were group 
O, D+ and crossmatched using an indirect antiglobulin test. 
On pretransplant Day –8, the patient was transfused with one 
RBC unit as his hemoglobin was 7.3 g/dL. On pretransplant 
Day –6, the patient received an additional two units of RBCs 
as his hemoglobin was again low, 6.8 g/dL. On pretransplant 
Day –5, the patient was found to have an anti-Jka. On further 
review it was found that one of the RBC units transfused 
on Day –6 was Jk(a+). At this point the patient’s direct 
antiglobulin test (DAT) was positive with IgG and C3 coating 
his RBCs. An eluate prepared from his RBCs contained anti-
Jka. On Day –4, the patient’s hemoglobin dropped from 8.4 
g/dL to 6 g/dL, his lactate dehydrogenase (LDH) rose to 942 
IU/L, and his total bilirubin rose to 2.8 mg/dL, all consistent 
with a delayed HTR (Fig. 1). He required five units of RBCs 
to maintain an adequate hemoglobin level over the next 3 
days. Given that the donor was Jk(a+), one dose of rituximab 
375 mg/m2 intravenously was added on Day –3 to prevent 
hemolysis after donor cell engraftment, as well as to reduce 
likelihood of passenger lymphocyte engraftment given the 
minor ABO incompatibility.
On pretransplant Day –2, the patient was also found 
to have an anti-K. No RBC units transfused during this 
admission were positive for K and the donor was K–, so this 
was not investigated further.
Materials and Methods
The patient’s ABO/D status was verified using 
monoclonal anti-A, -B, and -D reagents (BioClone, Ortho 
Clinical Diagnostics, Inc., Raritan, NJ). Initial screens for 
RBC antibodies were performed using the gel test (MTS 
Anti-IgG Card, Micro Typing Systems, Inc., Pompano Beach, 
FL). Monoclonal anti-Jka typing reagent (BioClone) was 
used to detect circulating Jk(a+) RBCs. Monoclonal anti-IgG, 
Fig. 1 Patient’s hemoglobin (Hb), lactate dehydrogenase (LDH), and bilirubin (T-bili) trend during transplant (occurring on Day 0). Each arrow 
at the top of the graph represents one transfused unit of red blood cells (RBCs). Solid arrows represent group O, D+, Jk(a–) RBC units; 
dashed arrow represents the one group O, D+, Jk(a+) RBC unit the patient received on Day –6. Anti-Jka was detected on Day –5.
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-C3d, polyspecific AHG (BioClone) were used to perform the 
DAT. Monoclonal Anti-AB containing the ES4 clone (anti-
A,B Murine Monoclonal Blend Series 1, Immucor Gamma, 
Norcross, GA) was used to type the patient’s ABO status after 
transplant. Both the gel test (MTS, Anti-IgG card, Ortho) and 
automated solid-phase capture assay (Galileo Echo; Immucor 
Gamma) were used to serially monitor the patient’s anti-Jka.
Results
By the day of transplantation, the patient’s hemoglobin 
had stabilized, and LDH and bilirubin were back to baseline. 
After transplantation, the patient received daily RBC 
transfusions with group O, D+, Jk(a–), K– RBCs from Day +4 
to Day +10; during this time there was no increase in markers 
of hemolysis, and the DAT remained negative. The patient 
achieved neutrophil engraftment on Day +11. On the same 
day, the patient first typed macroscopically as group O, D+ 
Jk(a–), a reflection of the 11 units of matched RBCs transfused 
during the preceding 2 weeks. On Day +21, the patient typed 
as O+, Jk(a+), indicating successful RBC reconstitution with 
donor erythropoiesis. Of note, with standard anti-A and anti-B 
typing, the patient forward typed as group O; however, with 
anti-A/B from an ES4 clone, the patient continued to show 1+ 
reactivity.
The patient’s anti-Jka was initially detected at a titer of 2 on 
Day –5. On serial monitoring, the titer decreased to 1 on Day 
+14 and became undetectable using gel-column assay (MTS 
Anti-IgG card, Ortho) on Day +17. Using solid-phase adherence 
assay (Capture, Immucor) the antibody was still detected until 
Day +40, converted to negative on Day +49, and remained 
so thereafter. Despite the persistence of detectable antibody, 
the patient required only two additional units of RBCs, one 
each on Day +24 and Day +40, and his posttransplant course 
remained uneventful otherwise.
Discussion
In this case, we report a patient who developed 
alloantibodies to both Jka and K before allogeneic HSCT. 
Neither of these antibodies was detectable during the 
time leading up to his admission for HSCT, during which 
period his transfusion support was provided outside of our 
institution. Although we do not know the Jka status of his prior 
transfusions, the prevalence of Jka and K suggest that at 
least 15 of the 20 units he received in the 3 months before 
admission would have been Jk(a+), and 2 units would have 
been K+. Unfortunately, the patient had almost completed his 
conditioning regimen for HSCT when the anti-Jka and -K were 
identified. This example of anti-Jka detected in our patient 
was clinically significant as evidenced by its ability to cause 
a delayed HTR, necessitating aggressive RBC transfusion 
support for a short time before transplant. There is scant 
literature available about the management of this type of 
situation.
The paucity of data regarding this issue likely is 
because patients undergoing HSCT have a low incidence of 
alloantibodies relative to the number of RBC transfusions 
they receive.9 The lack of alloimmunization is thought to be 
related to the intense chemotherapy given to patients for their 
underlying hematologic disease before transplant. Patients 
like ours constitute a minority of HSCT candidates who did 
not receive chemotherapy other than hydroxyurea before 
transplant, and this may have increased his likelihood of 
developing RBC alloantibodies.
Even when patients have alloantibodies, the traditional 
conditioning regimen before HSCT with chemotherapy or 
radiation will usually prevent these antibodies from being able 
to act effectively against donor RBCs. In one study, of 14 patients 
who were found to have alloantibodies before transplant, all 
but one no longer had detectable antibodies after transplant,9 
supporting the hypothesis that RBC alloantibodies can be 
eradicated in patients with HSCT.
However, as the indications for HSCT expand to include 
nonmalignant diseases such as thalassemia and sickle cell 
disease, and the use of reduced-intensity conditioning regimens 
continues to increase, non-ABO incompatibility issues may 
become a more prevalent problem in the future. For example, 
Borge et al.10 reported a patient with sickle cell disease who also 
had anti-Jka and received HSCT from a Jk(a+) donor. In this 
case the recipient had delayed RBC engraftment that persisted 
for more than 180 days after transplant. A nonmyeloablative 
conditioning regimen was used, consisting of alemtuzumab 
1 mg/kg and a single dose of total body irradiation 300 cGy, 
while oral sirolimus was used for prevention of GVHD.11
Although we also used a reduced-intensity conditioning 
regimen, we believe that in our patient the immunosuppressive 
agents, fludarabine and rituximab, were key in preventing 
potential problems. Fludarabine, a purine nucleoside analog, 
is a highly immunosuppressive agent that causes myelo-
suppression and prolonged reduction of CD4+ lymphocytes.12 
Rituximab is an anti-CD20 monoclonal antibody that 
selectively depletes circulating B cells, thus preventing antibody 
production.13 These two agents in combination effectively 
target all the immune cells required to generate an HTR. 
Eventually, with achievement of complete donor chimerism, 
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the donor immune cells would be expected to completely 
eliminate any residual alloantibody-producing cells.
For ABO-incompatible HSCT, delayed RBC engraftment 
has been associated with the length of time for the 
isohemagglutinin titers to decrease to clinically insignificant 
levels (1+ or lower in strength).14 In our case, the initial 
anti-Jka titer was 2 and became 1+ on Day +14, while donor 
erythropoiesis was established on Day +21. Thus, it may be 
useful to monitor antibody titers in the non-ABO–incompatible 
HSCT setting as an early indicator of whether successful donor 
erythropoiesis may be achieved. Whether high initial titers or 
persistent antibody detection warrants further intervention 
has yet to be determined.
Of note, the increased sensitivity of laboratory methods 
used in the detection of RBC antigens and antibodies may 
also cause RBC compatibility issues in HSCT to become more 
prevalent in the future. For instance, the anti-Jka in our patient 
could be detected on solid-phase capture assay up to 32 days 
after the gel-column assay became negative. Also, although the 
patient first typed as blood group O on Day +11, he continued 
to have detectable A and B on his RBCs when using the more 
sensitive assay with the ES4 clone.
In conclusion, we present the case of a patient with minor 
ABO and major non-ABO mismatch who successfully received 
matched unrelated donor HSCT. We believe that major non-
ABO mismatch is an underreported phenomenon that 
usually does not lead to clinically significant consequences, 
and clinicians should not be discouraged from using a major 
non-ABO–incompatible donor if such an incompatibility 
is discovered before HSCT. However, close monitoring of 
the recipients with markers for serum hemolysis should be 
performed during HSCT because severe hemolysis can occur 
in such situations. Monitoring antibody titers may also be 
helpful in predicting its clinical relevance. Depending on the 
level of concern, rituximab may be an additional strategy to 
use in this situation to avoid hemolysis and ensure successful 
RBC engraftment. We feel that this is a clinical situation that 
may become more common in the future given changing 
patterns of HSCT and the increased sensitivity of assays used 
to detect RBC antigens and antibodies.
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